ADXN Addex Therapeutics Ltd
Distress ·
Addex Therapeutics filed a Form NT 20-F on April 30, 2026, saying it will miss the deadline for its 2025 annual report. It reported a 2025 net loss of CHF 6.7 million, against a 2024 profit of CHF 7.1 million that the company ties to a sale of part of its business.
Addex Therapeutics amended its at-the-market agreement with H.C. Wainwright and filed a prospectus supplement for up to $3,300,000 of ADSs. The company reported CHF 2.2 million of cash at September 30, 2025 and says it covers expenses through mid-June 2026.
Addex Therapeutics Ltd. is a clinical-stage pharmaceutical company, founded in 2002 and registered in Geneva, Switzerland, focused on the development of orally available small molecule drug candidates. Its pipeline consists of proprietary clinical and preclinical candidates that the company or its partners are developing for diseases where no approved therapies exist or improved therapies are needed, including post-stroke sensorimotor recovery, traumatic brain injury (TBI) recovery, substance use disorders and chronic cough. Its lead development compound is dipraglurant, an mGlu5 negative allosteric modulator under evaluation for future development in post-stroke and TBI recovery. On April 30, 2025, the company entered into an option and collaboration agreement with Sinntaxis AB for an exclusive license covering mGlu5 inhibitors for brain injury recovery. Partner Indivior has licensed worldwide rights to a GABAB positive allosteric modulator for substance use disorder and has completed IND enabling studies on its selected compound. Addex plans its own GABAB program for chronic cough. The company also holds a 20% equity interest in Neurosterix US Holdings LLC, a company developing preclinical candidates for schizophrenia and mood disorders.
| Product or program | What it is | Stage |
|---|---|---|
| Dipraglurant | mGlu5 negative allosteric modulator for post-stroke and TBI recovery | under evaluation for future development |
| ADX71149 | mGlu2 positive allosteric modulator returned by partner Janssen | under evaluation |
| GABAB PAM for substance use disorder | Licensed to partner Indivior, which holds worldwide rights | IND enabling studies completed by partner |
| GABAB PAM for chronic cough | Company-selected compound with preclinical anti-tussive activity | planned IND enabling studies |
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | CHF 404,102 | CHF 1.6 million |
| Research and development | CHF 854,305 | CHF 1.2 million |
| Net income (loss) | CHF 7.1 million | -CHF 10.6 million |
| Cash from operations | -CHF 5.4 million | -CHF 8.0 million |
| Cash and equivalents | CHF 3.3 million | CHF 3.9 million |
| Short-term investments | CHF 6,496 | CHF 848 |
Our latest story on this, dated Dec 10, 2025: "Addex amends H.C. Wainwright ATM deal for up to $3,300,000 of ADSs". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 30, 2026: "Addex Therapeutics files late-filing notice for its 2025 annual report on Form 20-F". The story links the filing or release it is based on. Read the story.
Addex Therapeutics Ltd trades under the ticker ADXN on SIX.
Addex Therapeutics Ltd is listed on SIX. Our directory also records these other listings: GETTEX:APE; LSE:0QNV; NASDAQ:ADXN.
The SEC Central Index Key (CIK) for Addex Therapeutics Ltd is 1574232. Its filings are on SEC EDGAR.
147,831,814 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-05-15.
Our directory records Addex Therapeutics Ltd under Switzerland.
Our directory classifies Addex Therapeutics Ltd as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Addex Therapeutics Ltd is CH0029850754.
aibio.space lists Addex Therapeutics Ltd among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as V8.
Addex Therapeutics Ltd. is a clinical-stage pharmaceutical company, founded in 2002 and registered in Geneva, Switzerland, focused on the development of orally available small molecule drug candidates. Its pipeline consists of proprietary clinical and preclinical candidates that the company or its partners are developing for diseases where no approved therapies exist or improved therapies are needed, including post-stroke sensorimotor recovery, traumatic brain injury (TBI) recovery, substance use disorders and chronic cough.
Dipraglurant: mGlu5 negative allosteric modulator for post-stroke and TBI recovery Stage: under evaluation for future development.
ADX71149: mGlu2 positive allosteric modulator returned by partner Janssen Stage: under evaluation.
Our latest story on Addex Therapeutics, dated Apr 30, 2026: "Addex Therapeutics files late-filing notice for its 2025 annual report on Form 20-F". Addex Therapeutics filed a Form NT 20-F on April 30, 2026, saying it will miss the deadline for its 2025 annual report. It reported a 2025 net loss of CHF 6.7 million, against a 2024 profit of CHF 7.1 million that the company ties to a sale of part of its business. Source.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio